Ikris Pharmaceutical distributor | importer | Exporter supplier in india

 Ikris Pharma Network founded in 2014 and is based in Noida, India. We are one of the most reliable pharmaceutical companies for generic and branded medication (AstraZeneca, Pfizer, Sun Pharma etc.) supplies globally, making it a key player in the industry.

Ikris Pharma Network has a vast and wide range of 5000+ generic and branded drugs’ distribution services globally and is one of the top notch generic medicine suppliers. As a branded and generic medicine supplier, we specifically deal in all types of medicines i.e. tablet, capsules, liquid, topical, suppositories, drops, inhalers, injections, implants or patches etc.

Ikris Pharma Network offers to its clients (hospitals, dispensaries, patients, pharmacies) up to date pricing and inventory levels, order status. With Ikris Pharma Network, clients have access to direct reach to 5,000+ branded & generic medicine & health care products, and their pricing related deets and Simplified, intuitive, branded & generic drug ordering. 

In the industry of healthcare, we acknowledge that the one size usually does not fit all. And whether we're delivering pharmaceuticals or biopharmaceuticals, such as vaccines, we're completely aware that our patients depend on prompt as well as punctual delivery of their pharmaceutical products. We understand that our patients place trust in us to deliver for them. With Ikris Pharma Network, you can count on us to deliver for you.

Our efficiently optimised transportation and logistics services, large-scale global network, absolutely strict adherence to national and international compliance, and topmost or supreme end-to-end visibility allows/enables our clients’ supply chains with agility, balance, and speed to industry. 

Our experienced team is working relentlessly around the clock to ensure your precious and often life-saving shipments get to where they need to be - securely, at the appropriate and standard temperature, and on time.

From branded to Indian generic medicines, from RLD to Named Patient Program, Ikris Pharma Network delivers reliability for each customer across the industry. Have peace of mind in order to know that we have been delivering reliable solutions for our life science customers at the global level.

With proficient professionals, sophisticated processes, and impeccable reliability, it is our aspiration and liability to keep up to ensure our clients’ supply chains and businesses both succeed and thrive. 

We have assisted more than 50,000+ patients to date. We offer Validated and Customized solutions for cold chain products including vaccines We have Exported Indian Generic drugs to over 150+ nations including Romania, Brazil, China, South Africa, Italy, UK, Russia, Poland, Mexico, Latvia, etc.

Trodelvy: Uses, Dosage, Side Effects, Warnings

 Handling and Disposal: Trodelvy, often referred to as sacituzumab govitecan-hziy, comes in two doses: 180 mg and 200 mg. This medication is supplied in single-dose vials that are colored off-white to yellowish due to freeze-drying. Every vial is packaged separately within a carton. Included is one 180 mg vial with the NDC 55135-132-01 packaging code. It is imperative that these vials be kept in their respective containers and refrigerated between 2 and 8 degrees Celsius. There should never be a freeze on the medication. Because trodelvy can cause harm, it must be handled and disposed of with caution.  Numerous Trodelvy Side effects, including as anemia, lethargy, baldness, decreased appetite, coughing, nausea, vomiting, and diarrhoea, can also arise from trodelvy therapy.

Medication For Breast Cancer: Trodelvy is a crucial part of the treatment of metastatic triple-negative breast cancer (mTNBC). The active component that provides the therapeutic effects of trodelvy is sacituzumab govitecan. Both the specific protein and the monoclonal antibody that comprise this medication are necessary ingredients. Its primary benefits are for patients who have had at least two previous treatments for metastatic disease. Trodelvy is performed when surgical removal of the cancerous tissue is not feasible. The main medicinal ingredient is sacituzumab govitecan-hziy, which is a mix of a Trop-2-directed antibody and a topoisomerase inhibitor. It is important to keep in mind that Trodelvy can only be prescribed by licensed medical professionals. To buy trodelvy in India and make it accessible to a wider community, get in touch with The Indian Pharma.

Available as lyophilized powder: Trodelvy must be given in accordance with FDA-approved cycles, and the dosage is directly correlated with the patient's body weight. An intravenous dose of 10 mg/kg is given twice a day, on the first and the eighth day of each repeating 21-day cycle. Sacituzumab govitecan-hziy must be dosed accurately based on the patient's weight because it is a lyophilized powder. To create a concentration of 10 mg/mL, the vial is mixed with 20 mL of 0.9% sodium chloride injection, USP.Trodelvy 180mg is a reasonably priced medication that is readily accessible in the market 

Use In Chemotherapy: As part of the treatment regimen, a 5-HT3 receptor antagonist or an NK1 receptor antagonist is given as a premedication along with dexamethasone. This premedication approach lessens the chance that infusion reactions and chemotherapy will cause nausea and vomiting. The reason Trodelvy is so reasonably priced in India is its unique blend of a topoisomerase inhibitor and an anti-Trop-2 antibody. In individuals who have not responded well to earlier infusions, corticosteroids should be given. For additional information on the trodelvy cost , get in touch with Indian Pharma, a licensed distributor of this drug.

Potency of The Drug : Trodelvy offers hope to patients with advanced triple-negative breast cancer who have undergone at least two prior therapies. What makes it successful is how it interacts with SN-38, a small molecule that is crucial to its mode of action. The drug's potency is further increased by Trodelvy's monoclonal antibody's ability to bind to the Trop-2 protein present on a range of breast cancer cells. An additional advantage of Trodelvy is its cost-effectiveness, which is made possible by Indian Pharma. For individuals who would like additional information regarding the Trodelvy price. Along with anemia, more than one in five patients undergoing therapy for metastatic triple-negative breast cancer may also experience baldness, decreased appetite, coughing, stomach discomfort, and exhaustion.

Use Under Prescription: One of the potential negative effects of Trodelvy treatment is the emergence of severe or possibly fatal neutropenia. It is necessary to temporarily halt the administration of trodelvy in patients who have neutropenic fever or an absolute neutrophil count below 1500/mm3. It is essential to regularly evaluate blood cell counts during the course of treatment. It makes sense to utilize G-CSF for secondary prevention. In patients with feverish neutropenia, anti-infective treatment ought to be initiated promptly.  It's crucial to remember that the cost of Trodelvy injection is reasonably priced and accessible for those who have a valid prescription. 

 Therapeutic EffectsThe active component of Trodelvy that promotes its therapeutic effects is sacituzumab govitecan-hziy. Inactive ingredients in trodelvy include trehalose dihydrate, polysorbate 80, and 2-(N-morpholino) ethane sulfonic acid. 180 mg and 200 mg are the available strengths. Sacituzumab govitecan-hziy has shown promise in treating progesterone- and oestrogen-receptor-negative breast cancer because of its mechanism of action.For those who want to buy Trodelvy from India at a discount, you can get it through The Indian Pharma.

Negative Reactions: Those who have previously experienced a significant negative reaction to trodelvy shouldn't use it. There is a chance of serious hypersensitivity reactions with sacituzumab govitecan-hziy, including potentially lethal anaphylactic reactions. A few of the reactions that could happen are hypotension, wheezing, angioedema, swelling, pneumonitis, and skin reactions. To lessen the effects of the infusion, premedication is recommended. It's also advisable to have an emergency supply of medications and supplies on hand to manage any potential infusion-related complications, such as anaphylaxis, when administering sacituzumab govitecan-hziy. For more information on trodelvy injection price in India.

Tibsovo: Indication, Usage, Side-effects & Price

 The brand name medicine Tibsovo contains the active salt ivosidenib. It’s in a group of medicines named IDH1 inhibitors. (A medicine class is a group of drugs that acts identically.) Tibsovo is supplied as a tablet that needs to be swallowed. Tablets are commercially available in one strength: 250 milligrams (mg). You’ll likely take Tibsovo tablets once per day.

Indications of Tibsovo:

 Tibsovo is a once-daily prescription therapeutic drug used to treat adult patients with mutation IDH1 with:

Newly Diagnosed Acute Myeloid Leukemia AML):  In addition with azacitidine or as a single medicine (monotherapy) for newly diagnosed AML in adults 75 or older.

Relapsed or refractory AML: For adults with relapsed or refractory AML.

Cholangiocarcinoma (bile duct cancer): Patients who have received previous therapy and whose cancer has progressed.

The proposed dose of Tibsovo for AML and bile duct cancer is 500 mg orally once daily until the disease is progressive or in case of unacceptable toxicity. Administer it either with or without a meal. Do not use it with a high-fat food/meal because there may be a risk of an increase in ivosidenib concentration. It is not advisable to split or crush the tibsovo 250 mg tablets. Administer the medicine orally at about the same time each day. 

Side-effects of Tibsovo:

As per reports the most common side effects of AML are arthralgia, fatigue, leukocytosis, rash, cough, edema, diarrhea, nausea, dyspnea, mucositis, electrocardiogram QT prolonged, decreased appetite, myalgia, constipation, and pyrexia.

The most common side effects in patients with cholangiocarcinoma (bile duct cancer) are abdominal pain, fatigue, nausea, decreased appetite, rash, diarrhea, cough, ascites, anemia, and vomiting.

Cost of Tibsovo:

Tibsovo is an advanced imported medicine yet to be approved in India. It is natural for patients to look for the cost of Tibsovo in India. This medication should be officially procured through trusted and authorized importers like THE INDIAN PHARMA (TIP). For more inquiry, Call/WhatsApp: +91 9310090915, and we will help you calculate the total Tibsovo cost to buy this therapeutic product online legally.

Reference:

https://www.tibsovo.com/

What is T-cell Acute Lymphoblastic Leukemia

 T-ALL or T-cell acute lymphoblastic leukemia is a sort of acute lymphoblastic leukemia meaning that it is invasive and spreads rapidly. It impacts the lymphoid-cell-developing stem cells, in specific a type of white blood cell named T lymphocytes as opposed to acute lymphoblastic leukemia which commonly impacts B lymphocytes.

In this blood cancer, the immature white blood cells (WBCs) deposit in the bone marrow and eliminates normal white blood cells (WBCs), weakening the defense system. The cells may also deposit in the liver, lymph nodes, and spleen.

Causes and Risk Factors of T-ALL:

In maximum cases of T-cell acute lymphoblastic leukemia, there is no exact cause but it is necessary to understand that T-ALL neither is a complication that can be caught from someone else (contagious) nor passed on from a parent to a child (inherited)

Rick factors:

Age: most types of leukemia are so common in older individuals. The major exception to this is ALL, in which the highest incidence is in children, aged between about 2 to 5 years. T-ALL is most commonly found in slightly older children.

Being male: T-cell acute lymphoblastic leukemia (T-ALL) affects men more than women of all ages.

Signs and Symptoms of T-ALL:

There are no exclusive signs or symptoms which can help make T-ALL diagnosis easy. The most commonly reported signs and symptoms of T-ALL are caused by the bone marrow being not able to make adequate normal blood cells.

• Anaemia (because of lack of red blood cells)
• Tiredness, weakness, shortness of breath, palpitations, light-headedness
• Infections (because of lack of normal white blood cells)
• Infections are more frequent, more severe, and last longer
• Malaise, fever (general feeling of illness), and sweats
• Purpura (small bruises on the skin), bleeding gums, nosebleeds
• Bleeding and bruising (because of lack of platelets)

Other commonly reported signs and symptoms include:

T-ALL oftentimes causes swollen lymph nodes in the mediastinum (a middle part of the chest) which may impact breathing or the circulation

Drug Therapy for T-cell Acute Lymphoblastic Leukemia (T-ALL):

The drug Atriance contains the active substance Nelarabine. It is specifically licensed for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) that doesn’t respond to or relapses following initial therapy. It is commercially available as a 250 mg/50 mL (5 mg/mL) vial. Atriance 250 mg/50 mL can be effective, but about 15 % of individuals who receive treatment may develop neurotoxicity, which can cause serious and irreversible side effects. 

Tukysa: Warnings & Precautions

The therapeutic product Tukysa, containing the active substance Tucatinib, is a film-coated tablet that falls under the classification of tyrosine kinase inhibitors. Tukysa is commercially supplied as a 150 mg or 50 mg film-coated tablet. Seattle Genetics is credited for the medicine development and efforts in securing regulatory approval. 

Tukysa is a relatively new therapeutic product yet to be authorized in several world regions, including India. Tukysa cost in India depends on its availability and the regulatory constraints noted by the country of import.

Tukysa has been approved with trastuzumab and capecitabine to treat adult individuals with unresectable or metastatic HER2+ breast cancer, including those with brain metastases regimens previously treated with one or more anti-HER2-based.

The medicine is also authorized in conjunction with medicine trastuzumab to treat adult individuals with RAS wild-type HER2+ unresectable or metastatic colorectal cancer that has proceeded after treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

Tukysa is available on prescription only. The recommended dosage of Tukysa tablets is 300 mg, taken orally twice daily in 21-day cycles. 

Warnings and Precautions:

Diarrhea: The medication Tukysa can be responsible for causing severe diarrhea, including hypotension, 

dehydration, and acute kidney injury. In case diarrhea is reported, administer anti-diarrheal medicines. Perform diagnostic tests to exclude other potential causes of diarrhea. On behalf of the seriousness of diarrhea, doses can be interrupted, scaled down, or permanently stopped.

Hepatotoxicity: This therapeutic product can be responsible for causing severe hepatotoxicity. Monitor AST, ALT, and bilirubin before treatment and every 3 weeks during treatment. On behalf of the severity of hepatotoxicity, Tucatinib doses can be interrupted, scaled down, or permanently stopped.

Embryo-Fetal Toxicity: This tyrosine kinase inhibitor can cause fetal harm. Instruct pregnant women and women of reproductive age about the probable hazard to a fetus. Females of reproductive capacity and male patients with female partners of reproductive age should use suitable contraception during Tukysa therapy and at least 7 days after the eventual dose.

Note: The price of Tukysa is economical and one can order this medicine from multiple pharmaceutical suppliers in India. 

Reference: https://www.seagen.com/medicines/tukysa

Enhertu for Breast Cancer: Uses, Dosage, and Cost

Enhertu contains the active drug fam-trastuzumab deruxtecan-nxki. It is an FDA-approved HER2-directed antibody and topoisomerase inhibitor conjugate. Commercially supplied as 100 mg vials in the market, it may also be known as trastuzumab deruxtecan, or T-DXd. Enhertu 100 mg is developed by Daiichi Sankyo and is promoted by AstraZeneca (AZ) globally.

Enhertu Uses for Breast Cancer: Enhertu is approved by the FDA for the treatment of adults with breast cancer that is either:

HER2-positive: These are tumors that grow quickly because of higher levels of a protein named  HER2 or human epidermal growth factor receptor 2. As per Breast Cancer Foundation, 15-20 % of breast cancers are HER2-positive, and these cancers tend to progress faster.

HER2-low: This newer term basically describes tumors that have HER2 but are not sufficient to be considered positive. Earlier these tumors would have been classified as HER2-negative. Now up to 60 percent of breast cancers are HER2-low.

More specifically, the medicine Enhertu injection is considered when these tumors are either metastatic (meaning it has spread from their initial location to distant body parts), or unresectable (meaning they can't be removed surgically).

Prior to starting Enhertu, patients must also have already been treated with other therapies (anti-HER2 therapy for HER2 +Ve cancer, or chemotherapy for HER2-low) for metastatic cancer, or had a recurrence within six months following completing these previous therapies.

Other Uses of Enhertu (fam-trastuzumab deruxtecan-nxki):

 Enhertu 100 mg injection may also be given to individuals who have:

• NSCLC, that has a specific mutation named HER2, which is unable to be removed with surgery or has metastasized, and has already been treated.
• HER2 +Ve gastric or gastroesophageal junction adenocarcinoma stomach cancer that has spread and has already been treated.

Enhertu Dosage & Administration:

Enhertu is typically administered intravenously (IV) through a method known as infusion therapy. It is an ADC, a type of targeted medicine, meaning it travels to the tumor and releases chemo to the cells that produce excess HER2, directly destroying the cells that cause harm to the body.  A dose of 5.4 mg/kg of body weight is typically given once every 21 days. Treatment duration may vary, with 7 months being the midrange treatment.

Enhertu Injection Cost & Availability:

Enhertu cost in India is mostly influenced due to the lack of easy access. Patients can consider several options that are cost-effective. Enhertu is a lifesaving medicinal product that is not (yet) available in India. But can be legally accessed from an experienced service provider Indian Pharma Network (IPN). We are specialized in delivering specialty medicinal products like sourcing Enhertu 100 mg injection in India.

Kindly WhatsApp/Call: +91 9310090915 or dial our TOLL-FREE Number: 1800-889-1064 to buy Enhertu Online in India and other countries where the medicine is not (yet) approved.

Atriance Suppliers in India

For the proper handling and disposal of cytotoxic anti-tumour pharmaceuticals, the following procedures should be followed: 

Staff members must receive training on handling and transporting the medication.

You can now buy Atriance injection online in India through The Indian Pharma Network at an affordable price by going to our website at https://www.indianpharmanetwork.in/. We are a team of highly skilled specialists with more than 20 years of expertise in distributing speciality pharmaceuticals.

Atriance: Distributors in India

Despite the low Atriance injection price, this medicine is under closer observation. Healthcare professionals should report any potential harmful responses. There were insufficient numbers of patients 65 and older in clinical investigations using nelarabine to ascertain whether their responses differed from those of younger patients. Nelarabine was administered to a child patient in clinical tests at a dose of 75 mg/kg daily for 5 days, to 5 adult patients at a dose of 60 mg/kg (roughly 2,400 mg/m2) daily for 5 days, and to 2 additional adults on days 1, 3, and 5. For more information on Atriance, contact us by email at info@indianpharmanetwork.in.

Atriance: An FDA-approved medication

The FDA approved the medicine Nelarabine in 2005. According to an exploratory analysis, getting older—particularly older than 65—seemed linked to a higher incidence of neurological adverse events. Although it is packaged as Atriance 250mg 50 ml, overdose can occasionally occur. However, there haven't been any overdose reports. Nelarabine overdose is likely to result in fatal myelosuppression, severe neurotoxicity, and other side effects. Two patients who received 2200 mg/m2 on days 1, 3, and 5 every 21 days experienced significant grade 3 ascending sensory neuropathy.